Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA – Get Free Report) crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $0.11 and traded as high as $0.1349. Hepion Pharmaceuticals shares last traded at $0.1150, with a volume of 32,939 shares trading hands.
Hepion Pharmaceuticals Stock Performance
The stock has a market capitalization of $1.32 million, a P/E ratio of -0.03 and a beta of 1.52. The firm has a fifty day moving average price of $0.11 and a two-hundred day moving average price of $0.07.
Hepion Pharmaceuticals (NASDAQ:HEPA – Get Free Report) last issued its quarterly earnings data on Monday, November 16th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($200.00) by $199.94.
Hepion Pharmaceuticals Company Profile
Hepion Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing treatments for chronic liver diseases. Its research centered on rencofilstat, an investigational oral cyclophilin inhibitor studied for conditions including nonalcoholic steatohepatitis (NASH) and liver fibrosis. The company was formerly known as ContraVir Pharmaceuticals and adopted the Hepion name in 2019. Its work included clinical development of rencofilstat; the candidate was investigational and had not been approved as a treatment.
Recommended Stories
- Five stocks we like better than Hepion Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Hepion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hepion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
